Nomura Asset Management Co. Ltd. Has $29.19 Million Position in IDEXX Laboratories, Inc. $IDXX

Nomura Asset Management Co. Ltd. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 43,144 shares of the company’s stock after selling 9,958 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in IDEXX Laboratories were worth $29,188,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Portland Global Advisors LLC grew its position in IDEXX Laboratories by 323.7% during the fourth quarter. Portland Global Advisors LLC now owns 8,147 shares of the company’s stock worth $5,512,000 after buying an additional 6,224 shares in the last quarter. Railway Pension Investments Ltd grew its position in IDEXX Laboratories by 10.0% during the fourth quarter. Railway Pension Investments Ltd now owns 326,080 shares of the company’s stock worth $220,603,000 after buying an additional 29,550 shares in the last quarter. MUFG Securities EMEA plc grew its position in IDEXX Laboratories by 113.8% during the fourth quarter. MUFG Securities EMEA plc now owns 3,274 shares of the company’s stock worth $2,215,000 after buying an additional 1,743 shares in the last quarter. Sfmg LLC grew its position in IDEXX Laboratories by 68.0% during the fourth quarter. Sfmg LLC now owns 1,045 shares of the company’s stock worth $707,000 after buying an additional 423 shares in the last quarter. Finally, Wormser Freres Gestion grew its position in IDEXX Laboratories by 671.4% during the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after buying an additional 47 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.6%

NASDAQ IDXX opened at $566.79 on Tuesday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a twelve month low of $504.56 and a twelve month high of $769.98. The company has a market cap of $44.71 billion, a price-to-earnings ratio of 41.74, a price-to-earnings-growth ratio of 3.27 and a beta of 1.56. The business’s fifty day moving average is $564.32 and its 200 day moving average is $635.65.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the business posted $2.91 EPS. IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on IDXX. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Barclays reduced their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. UBS Group reduced their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Piper Sandler reduced their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.